---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: VANGUARD"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: VANGUARD. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 14 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence/vanguard"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: VANGUARD

<a id="heading-3.1.7"></a>

## 3.1.7 VANGUARD

<a id="heading-3.1.7.1"></a>

### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

#### Prophylactic treatment objective

> “prophylactic treatment for attacks due to hereditary angioedema (HAE).”

Source: [CSL (2023)](https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE)

<a id="heading-3.1.7.2"></a>

### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

#### Number of trial centers

> “28 centers”

Source: [FDA Drug Trials Snapshot ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)

<a id="heading-3.1.7.3"></a>

### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

#### Study design and allocation ratio

> “randomised, double-blind, placebo-controlled”
> “(3:2)”

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.7.4"></a>

### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

#### Eligibility: age and run-in attacks

> “12 years of age and older”
> “two or more acute HAE attacks”

Source: [FDA Drug Trials Snapshot ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)

<a id="heading-3.1.7.5"></a>

### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

#### Administration schedule

> “monthly subcutaneous injections of garadacimab”

Source: [CSL (2023)](https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE)

<a id="heading-3.1.7.6"></a>

### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

#### 3.1.7.6.1 Rationale for Using Monthly HAE Attack Rate as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

##### Primary endpoint: six-month observation

> “number of HAE attacks per month”

Source: [FDA Drug Trials Snapshot ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)

<a id="heading-3.1.7.7"></a>

### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

#### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

##### Randomized and included populations

| Population | Participants |
| --- | --- |
| Randomized | “65” |
| Garadacimab included | “39” |
| Placebo included | “25” |

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.7.7.2"></a>

#### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

##### Safety population: minimum treatment exposure

> “at least one dose”

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.7.8"></a>

### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

#### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

##### Randomization error

> “One patient was randomly assigned in error”

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.7.8.2"></a>

#### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

##### Baseline sex distribution

| Characteristic | Participants, n (%) |
| --- | --- |
| Female | “38 (59%)” |

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.7.8.3"></a>

#### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

##### Published monthly attack rates and relative treatment effect

| Outcome | Reported value |
| --- | --- |
| Garadacimab: mean monthly attack rate | “0·27” |
| Placebo: mean monthly attack rate | “2·01” |
| Difference in means, percent | “-87%” |

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/)

<a id="heading-3.1.7.8.4"></a>

#### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.7.8.4-1"></a>

##### AE-QoL total score by attack-free status: post hoc analysis

> “Patients ages ≥ 18 years completed the Angioedema Quality of Life (AE-QoL) questionnaire in both studies; scores were evaluated post hoc by attack-free status.”
> “In the pivotal phase III and phase III OLE studies, 62% and 60% of patients, respectively, were attack-free.”
> “In the pivotal phase III study, the mean AE-QoL total score improved with garadacimab, from 38.8 (day 1) to 6.6 (month 6) for attack-free patients (n = 19) and to 18.4 for patients with one or more attacks (n = 14) versus a change in mean AE-QoL total score from 43.7 to 40.5 with placebo (n = 20).”

Source: [Staubach et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40380356/)

<a id="heading-3.1.7.8.5"></a>

#### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

##### Nasopharyngitis adverse reactions

| Treatment | Participants, n (%) |
| --- | --- |
| Garadacimab, n=39 | “8 (21)” |
| Placebo, n=25 | “3 (12)” |

Source: [FDA Drug Trials Snapshot ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry)

<a id="heading-3.1.7.9"></a>

### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

#### Summary

Of 65 randomized participants, 64 were included in the reported comparison (39 receiving garadacimab and 25 receiving placebo) after one participant was randomized in error. Allocation was 3:2 across 28 centers, and the placebo group of 25 participants limits precision for between-group estimates and for uncommon adverse events. Eligibility required “two or more acute HAE attacks”. The primary endpoint, the number of HAE attacks per month, does not describe outcomes over longer treatment. No health-related quality of life result for this trial was identified. Garadacimab was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, run-in requirements, baseline attack rates, and observation periods can affect the reported attack rates.

Source: [Craig et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36868261/); [FDA Drug Trials Snapshot ANDEMBRY (2025)](https://www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-andembry); [CSL (2023)](https://newsroom.csl.com/2023-03-01-The-Lancet-Publishes-Pivotal-Phase-3-Data-on-CSLs-First-in-Class-Garadacimab-for-HAE)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
